Premarket Dose Optimization Precedent In Oncology Likely Not Available Yet

 
• By Derrick Gingery
  
Mirat Shah at the Friends of Cancer Research Annual Meeting
The FDA's Mirat Shah discusses Project Optimus during the Friends of Cancer Research Annual Meeting. • Source: Screenshot of internet broadcast

More from Approval Standards

More from Pathways & Standards